ReviewJournal of Alzheimer's disease : JAD2026
Decoding the mechanisms of amyloid-β in synaptic toxicity.
Review in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid-β (Aβ) aggregation is considered a central hallmark in the pathophysiology of Alzheimer's disease (AD). Aβ protein aggregates disrupt synaptic architecture, calcium homeostasis, and mitochondrial function, leading to excitotoxicity and synaptic plasticity deficits. Animal models and human studies reveal that Aβ-induced alterations in synaptic activity and neuronal circuit function appear before irreversible damage and the onset of cognitive impairment. This review examines the multifaceted effects of Aβ on synaptic and neuronal circuits across its distinct aggregation states, including monomeric, oligomeric, protofibrillar, and fibrillar forms. Its novelty lies in providing a comprehensive map of Aβ-induced mechanisms that disrupt neuronal electrical function, based on electrophysiological evidence from neuronal cultures, animal models, and patient studies, with a particular focus on preclinical stages of cognitive decline. We suggest that the Aβ-induced synaptic toxicity could serve, first, as a complementary biomarker of brain deterioration and second, as a readout of current AD therapies. This could potentially lead to better outcomes in AD treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.